Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$285.41 +3.5%	$290.57	$253.30 ▼ $339.17	$153.65B	0.49	1.99 million shs	8.73 million shs
BIIB Biogen	$142.50 -0.9%	$135.01	$110.04 ▼ $200.37	$20.89B	0.11	1.49 million shs	3.75 million shs
GILD Gilead Sciences	$114.09 +0.4%	$114.10	$81.83 ▼ $121.83	$141.56B	0.36	5.84 million shs	12.58 million shs
ILMN Illumina	$102.75 -0.3%	$99.78	$68.70 ▼ $156.66	$15.79B	1.43	1.31 million shs	3.62 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+3.47%	+3.26%	-3.72%	-1.35%	-14.27%
BIIB Biogen	-0.91%	-1.63%	+2.53%	+12.17%	-27.88%
GILD Gilead Sciences	+0.41%	-0.40%	-3.91%	+5.15%	+36.00%
ILMN Illumina	-0.27%	+8.02%	+1.93%	+13.55%	-21.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$285.41 +3.5%	$290.57	$253.30 ▼ $339.17	$153.65B	0.49	1.99 million shs	8.73 million shs
BIIB Biogen	$142.50 -0.9%	$135.01	$110.04 ▼ $200.37	$20.89B	0.11	1.49 million shs	3.75 million shs
GILD Gilead Sciences	$114.09 +0.4%	$114.10	$81.83 ▼ $121.83	$141.56B	0.36	5.84 million shs	12.58 million shs
ILMN Illumina	$102.75 -0.3%	$99.78	$68.70 ▼ $156.66	$15.79B	1.43	1.31 million shs	3.62 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+3.47%	+3.26%	-3.72%	-1.35%	-14.27%
BIIB Biogen	-0.91%	-1.63%	+2.53%	+12.17%	-27.88%
GILD Gilead Sciences	+0.41%	-0.40%	-3.91%	+5.15%	+36.00%
ILMN Illumina	-0.27%	+8.02%	+1.93%	+13.55%	-21.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.24	Hold	$304.43	6.66% Upside
BIIB Biogen	2.32	Hold	$181.65	27.48% Upside
GILD Gilead Sciences	2.89	Moderate Buy	$117.17	2.70% Upside
ILMN Illumina	2.21	Hold	$123.06	19.76% Upside

Current Analyst Ratings Breakdown

Latest AMGN, BIIB, GILD, and ILMN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2025	GILD Gilead Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$135.00 ➝ $145.00
9/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$115.00 ➝ $118.00
9/12/2025	GILD Gilead Sciences	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$136.00 ➝ $143.00
9/5/2025	GILD Gilead Sciences	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Moderate Buy
9/4/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
9/3/2025	AMGN Amgen	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform
9/2/2025	ILMN Illumina	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$124.00
8/25/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$328.00 ➝ $342.00
8/19/2025	GILD Gilead Sciences	Daiwa America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/19/2025	GILD Gilead Sciences	Daiwa Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$128.00
8/14/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$115.00 ➝ $118.00

(Data available from 9/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.60	$30.36 per share	9.40	$10.93 per share	26.11
BIIB Biogen	$9.68B	2.16	$23.10 per share	6.17	$114.71 per share	1.24
GILD Gilead Sciences	$28.75B	4.92	$6.87 per share	16.61	$15.44 per share	7.39
ILMN Illumina	$4.37B	3.61	$4.69 per share	21.90	$14.96 per share	6.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$12.23	23.34	13.34	2.48	18.96%	174.71%	13.12%	10/29/2025 (Estimated)
BIIB Biogen	$1.63B	$10.46	13.62	8.63	1.12	15.31%	13.85%	8.32%	10/29/2025 (Estimated)
GILD Gilead Sciences	$480M	$5.02	22.73	14.07	0.77	21.86%	50.99%	17.24%	11/5/2025 (Estimated)
ILMN Illumina	-$1.22B	$7.90	13.01	19.91	2.31	29.36%	28.93%	10.74%	11/3/2025 (Estimated)

Latest AMGN, BIIB, GILD, and ILMN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	GILD Gilead Sciences	$1.96	$2.01	+$0.05	$1.55	$6.95 billion	$7.08 billion
8/5/2025	Q2 2025	AMGN Amgen	$5.28	$6.02	+$0.74	$2.65	$8.86 billion	$9.18 billion
7/31/2025	Q2 2025	BIIB Biogen	$3.93	$5.47	+$1.54	$4.33	$2.32 billion	$2.65 billion
7/31/2025	Q2 2025	ILMN Illumina	$1.02	$1.19	+$0.17	$1.50	$1.12 billion	$1.06 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.34%	N/A	77.84%	14 Years
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	2.77%	N/A	62.95%	10 Years
ILMN Illumina	N/A	N/A	N/A	N/A	N/A

Latest AMGN, BIIB, GILD, and ILMN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	GILD Gilead Sciences	quarterly	$0.79	2.81%	9/15/2025	9/15/2025	9/29/2025
8/1/2025	AMGN Amgen	quarterly	$2.38	3.21%	8/22/2025	8/22/2025	9/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	7.24	1.31	0.98
BIIB Biogen	0.36	2.50	1.79
GILD Gilead Sciences	1.13	1.32	1.15
ILMN Illumina	0.66	1.81	1.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BIIB Biogen	87.93%
GILD Gilead Sciences	83.67%
ILMN Illumina	89.42%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.76%
BIIB Biogen	0.18%
GILD Gilead Sciences	0.27%
ILMN Illumina	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	538.36 million	534.27 million	Optionable
BIIB Biogen	7,605	146.62 million	146.35 million	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
ILMN Illumina	9,030	153.70 million	149.70 million	Optionable

AMGN, BIIB, GILD, and ILMN Headlines

Recent News About These Companies

New Bill: Senator Lisa Murkowski introduces S. 2760: Reducing Hereditary Cancer Act of 2025

September 19 at 11:50 AM | quiverquant.comQ

Exchange Traded Concepts LLC Grows Stock Holdings in Illumina, Inc. $ILMN

September 19 at 7:44 AM | marketbeat.com

Illumina, Inc. $ILMN Shares Purchased by Swedbank AB

September 19 at 4:39 AM | marketbeat.com

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

September 18 at 9:15 AM | prnewswire.com

Sivia Capital Partners LLC Makes New Investment in Illumina, Inc. $ILMN

September 18 at 7:32 AM | marketbeat.com

Radnor Capital Management LLC Makes New $2.08 Million Investment in Illumina, Inc. $ILMN

September 18 at 6:42 AM | marketbeat.com

Pallas Capital Advisors LLC Acquires 16,800 Shares of Illumina, Inc. $ILMN

September 18 at 4:39 AM | marketbeat.com

Gateway Investment Advisers LLC Sells 8,804 Shares of Illumina, Inc. $ILMN

September 18 at 4:28 AM | marketbeat.com

Voya Investment Management LLC Sells 12,213 Shares of Illumina, Inc. $ILMN

September 18 at 3:24 AM | marketbeat.com

Swedbank AB Cuts Position in Illumina, Inc. $ILMN

September 17 at 3:45 AM | marketbeat.com

Acadian Asset Management LLC Buys 20,784 Shares of Illumina, Inc. $ILMN

September 17 at 3:20 AM | marketbeat.com

Partnership Wealth Management LLC Grows Stock Position in Illumina, Inc. $ILMN

September 16, 2025 | marketbeat.com

OMNI 360 Wealth Inc. Makes New $364,000 Investment in Illumina, Inc. $ILMN

September 16, 2025 | marketbeat.com

Kera Capital Partners Inc. Makes New Investment in Illumina, Inc. $ILMN

September 16, 2025 | marketbeat.com

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $155.54 Million Stock Position in Illumina, Inc. $ILMN

September 15, 2025 | marketbeat.com

Plato Investment Management Ltd Sells 2,855 Shares of Illumina, Inc. $ILMN

September 14, 2025 | marketbeat.com

Illumina, Inc. $ILMN Shares Acquired by Bayforest Capital Ltd

September 14, 2025 | marketbeat.com

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $4.77 Million Stock Holdings in Illumina, Inc. $ILMN

September 14, 2025 | marketbeat.com

Why Illumina (ILMN) Stock Is Falling Today

September 12, 2025 | msn.com

Illumina Inc. stock underperforms Friday when compared to competitors

September 12, 2025 | marketwatch.com

Illumination and Nintendo Announce the New Animated Film Based on the World of Super Mario Bros. Will Be Titled The Super Mario Galaxy Movie

September 12, 2025 | financialpost.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AMGN, BIIB, GILD, and ILMN Company Descriptions

Amgen NASDAQ:AMGN

$285.41 +9.58 (+3.47%)

Closing price 09/19/2025 04:00 PM Eastern

Extended Trading

$284.88 -0.54 (-0.19%)

As of 09/19/2025 07:59 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen NASDAQ:BIIB

$142.50 -1.31 (-0.91%)

Closing price 09/19/2025 04:00 PM Eastern

Extended Trading

$142.38 -0.12 (-0.09%)

As of 09/19/2025 07:57 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Gilead Sciences NASDAQ:GILD

$114.09 +0.47 (+0.41%)

Closing price 09/19/2025 04:00 PM Eastern

Extended Trading

$113.75 -0.34 (-0.30%)

As of 09/19/2025 07:54 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Illumina NASDAQ:ILMN

$102.75 -0.28 (-0.27%)

Closing price 09/19/2025 04:00 PM Eastern

Extended Trading

$102.99 +0.24 (+0.23%)

As of 09/19/2025 07:58 PM Eastern

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMGN, BIIB, GILD, and ILMN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMGN, BIIB, GILD, and ILMN Earnings

Compare Dividends

Latest AMGN, BIIB, GILD, and ILMN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMGN, BIIB, GILD, and ILMN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AMGN, BIIB, GILD, and ILMN Company Descriptions

Amgen NASDAQ:AMGN

Biogen NASDAQ:BIIB

Gilead Sciences NASDAQ:GILD

Illumina NASDAQ:ILMN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools